DDInter1607 DDInter393
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Ritonavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Ritonavir {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Clarithromycin
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Clarithromycin
Ritonavir {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Ritonavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Troleandomycin
Troleandomycin {u} (Compound) resembles {v} (Compound) Clarithromycin
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A7
CYP3A7 {u} (Gene) is bound by {v} (Compound) Erythromycin
Erythromycin {u} (Compound) resembles {v} (Compound) Clarithromycin
Ritonavir {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is regulated by {v} (Gene) MEF2C
MEF2C {u} (Gene) is upregulated by {v} (Compound) Clarithromycin
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Zonisamide
Zonisamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Ritonavir (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Clarithromycin (Compound)
Ritonavir (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Clarithromycin (Compound)
Ritonavir (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Clarithromycin (Compound)
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Troleandomycin (Compound) and Troleandomycin (Compound) resembles Clarithromycin (Compound)
Ritonavir (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Erythromycin (Compound) and Erythromycin (Compound) resembles Clarithromycin (Compound)
Ritonavir (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is regulated by MEF2C (Gene) and MEF2C (Gene) is upregulated by Clarithromycin (Compound)
Ritonavir (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Ritonavir (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Zonisamide (Compound) and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin